These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 31053154)

  • 21. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
    Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
    Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
    Bouwman L; Sepodes B; Leufkens H; Torre C
    Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.
    Post HC; Schutte T; van Oijen MGH; van Laarhoven HWM; Hollak CEM
    ESMO Open; 2023 Apr; 8(2):101208. PubMed ID: 37030113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of moral reasons on orphan drug reimbursement.
    Zimmermann BM; Eichinger J; Baumgartner MR
    Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Access to orphan drugs - comparison across Balkan countries.
    Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
    Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of new medicines in Spain and comparison with other European countries.
    Epstein D; Espín J
    Gac Sanit; 2020; 34(2):133-140. PubMed ID: 31027840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient access to orphan drugs in France.
    Bourdoncle M; Juillard-Condat B; Taboulet F
    Orphanet J Rare Dis; 2019 Feb; 14(1):47. PubMed ID: 30777102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010-2019.
    Foltanova T; Majernik A; Malikova E; Kosirova S
    Front Pharmacol; 2022; 13():768325. PubMed ID: 35153774
    [No Abstract]   [Full Text] [Related]  

  • 33. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
    de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
    Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
    Iglesias-López C; Agustí A; Vallano A; Obach M
    Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Market uptake of orphan drugs--a European analysis.
    Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
    J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries.
    Stawowczyk E; Malinowski KP; Kawalec P; Bobiński R; Siwiec J; Panteli D; Eckhardt H; Simoens S; Agusti A; Dooms M; Pilc A
    Front Pharmacol; 2019; 10():1279. PubMed ID: 31827433
    [No Abstract]   [Full Text] [Related]  

  • 37. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
    Hutchings A; Schey C; Dutton R; Achana F; Antonov K
    Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
    Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
    Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.